司库奇尤单抗与乌司奴单抗治疗银屑病关节炎的直接比较
该回顾性全国多中心队列研究纳入406例银屑病关节炎患者(乌司奴单抗245例、司库奇尤单抗161例),采用倾向性评分方法比较真实世界药物留存率。结果显示司库奇尤单抗中位留存时间14.7个月优于乌司奴单抗的9.4个月,加权HR=1.42(95%CI 1.07,1.92;P=0.015),亚组分析中该差异仅见于联合甲氨蝶呤时。
要点
- 司库奇尤单抗2年留存率38.0%,乌司奴单抗26.4%,加权HR=1.42(95%CI 1.07,1.92;P=0.015)。
- 联合甲氨蝶呤亚组:司库奇尤单抗优于乌司奴单抗(HR=2.20;95%CI 1.30,3.51;P=0.001)。
- 单药治疗亚组两组无显著差异(HR=1.06;95%CI 0.74,1.53;P=0.75)。
核心结论
- 在银屑病关节炎中,司库奇尤单抗的真实世界药物留存率高于乌司奴单抗。
- 亚组分析显示该差异仅存在于联合甲氨蝶呤治疗的患者中。
研究设计与样本
- 回顾性、全国性、多中心队列研究,纳入2011年1月至2019年4月启动乌司奴单抗或司库奇尤单抗且随访≥6个月的银屑病关节炎患者。
- 共纳入406例患者,其中乌司奴单抗245例、司库奇尤单抗161例;采用预设倾向性评分方法校正潜在混杂因素后比较留存率。
主要发现
- 司库奇尤单抗组中位留存时间14.7个月,乌司奴单抗组9.4个月。
- 2年留存率司库奇尤单抗组38.0%,乌司奴单抗组26.4%。
- 加权风险比(HR)=1.42(95%CI 1.07,1.92;P=0.015), favoring 司库奇尤单抗。
- 联合甲氨蝶呤亚组:HR=2.20(95%CI 1.30,3.51;P=0.001),司库奇尤单抗留存率显著更高。
- 单药治疗亚组:HR=1.06(95%CI 0.74,1.53;P=0.75),两组无显著差异。
关键数值与推荐
- 因无效停药的比例:司库奇尤单抗组91.7%,乌司奴单抗组82.4%。
- 因不良事件停药的比例:司库奇尤单抗组12.2%,乌司奴单抗组7.7%。
临床怎么用
- 在银屑病关节炎真实世界治疗中,司库奇尤单抗的持久性优于乌司奴单抗,尤其在与甲氨蝶呤联合使用时。
- 选择生物制剂时需结合是否联合甲氨蝶呤及患者个体情况综合评估。
局限性
- 本研究为回顾性队列研究,可能存在未测量的混杂因素。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. METHODS: In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected. RESULTS: A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts. CONCLUSION: In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.
引用
- Letarouilly JG, Flachaire B, Labadie C, et al. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology (Oxford). 2021. PMID: 33232465. doi:10.1093/rheumatology/keaa710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。